Cargando…

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development

Emerging drug resistance and high-attrition rates in early and late stage drug development necessitate accelerated development of antimalarial compounds. However, systematic and meaningful translation of drug efficacy and host-parasite dynamics between preclinical testing stages is missing. We devel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burgert, Lydia, Rottmann, Matthias, Wittlin, Sergio, Gobeau, Nathalie, Krause, Andreas, Dingemanse, Jasper, Möhrle, Jörg J., Penny, Melissa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064600/ https://www.ncbi.nlm.nih.gov/pubmed/32157151 http://dx.doi.org/10.1038/s41598-020-61304-8

Ejemplares similares

Parasite-Host Dynamics throughout Antimalarial Drug Development Stages Complicate the Translation of Parasite Clearance
por: Burgert, Lydia, et al.
Publicado: (2021)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations
por: Wicha, Sebastian G., et al.
Publicado: (2022)

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects
por: Krause, Andreas, et al.
Publicado: (2016)

Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection
por: Collins, Katharine A, et al.
Publicado: (2020)

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development
por: Andrews, Kayla Ann, et al.
Publicado: (2020)

The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro
por: Walz, Annabelle, et al.
Publicado: (2023)

A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria
por: Cherkaoui‐Rbati, Mohammed H., et al.
Publicado: (2022)

Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention
por: Burgert, Lydia, et al.
Publicado: (2022)

Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048
por: McCarthy, James S, et al.
Publicado: (2020)

Development and application of a PBPK modeling strategy to support antimalarial drug development
por: Abla, Nada, et al.
Publicado: (2023)

The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites
por: Delves, Michael, et al.
Publicado: (2012)

Lost in translation? Bridging the preclinical / clinical divide
por: Baker, Mark, et al.
Publicado: (2012)

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
por: McCarthy, James S, et al.
Publicado: (2017)

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
por: de Vries, Laura E., et al.
Publicado: (2022)

A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers
por: McCarthy, James S., et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study
por: Abd‐Rahman, Azrin N., et al.
Publicado: (2020)

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial
por: Phyo, Aung Pyae, et al.
Publicado: (2016)

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362
por: Lowe, Martin A., et al.
Publicado: (2022)

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020)

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling
por: Le Bihan, Amélie, et al.
Publicado: (2016)

Drug Development for Pediatric Populations: Regulatory Aspects
por: Zisowsky, Jochen, et al.
Publicado: (2010)

Expanding the antimalarial toolkit: Targeting host–parasite interactions
por: Langhorne, Jean, et al.
Publicado: (2016)

Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle
por: Favuzza, Paola, et al.
Publicado: (2020)

Antiviral mechanism of preclinical antimalarial compounds possessing multiple antiviral activities
por: Gu, Weilin, et al.
Publicado: (2021)

Ancient Chinese Methods Are Remarkably Effective for the Preparation of Artemisinin-Rich Extracts of Qing Hao with Potent Antimalarial Activity
por: Wright, Colin W., et al.
Publicado: (2010)

Exposing Anopheles mosquitoes to antimalarials blocks Plasmodium parasite transmission
por: Paton, Douglas G., et al.
Publicado: (2019)

Repurposing antimalarial artesunate for the prophylactic treatment of depression: Evidence from preclinical research
por: Huang, Shihao, et al.
Publicado: (2022)

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
por: Llanos-Cuentas, Alejandro, et al.
Publicado: (2018)

Driving antimalarial design through understanding of target mechanism
por: Calic, Petar P. S., et al.
Publicado: (2020)

Probability of emergence of antimalarial resistance in different stages of the parasite life cycle
por: Pongtavornpinyo, Wirichada, et al.
Publicado: (2009)

Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination
por: Mathews, Emily S., et al.
Publicado: (2018)

Targeting malaria parasite invasion of red blood cells as an antimalarial strategy
por: Burns, Amy L, et al.
Publicado: (2019)

Daily rhythms of both host and parasite affect antimalarial drug efficacy
por: Owolabi, Alíz T Y, et al.
Publicado: (2021)

Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

Confidence and Prediction Intervals for Pharmacometric Models
por: Kümmel, Anne, et al.
Publicado: (2018)

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y(12) receptor between selatogrel and oral P2Y(12) antagonists
por: Henrich, Andrea, et al.
Publicado: (2021)

Monoclonal Antibodies That Recognize the Alkylation Signature of Antimalarial Ozonides OZ277 (Arterolane) and OZ439 (Artefenomel)
por: Jourdan, Joëlle, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qlh75nslccgvkpbu6lasirisl4